REFERENCES
1.-Tentori F, Blayney MJ, Albert JM, et al. Mortality risk. for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2008;52(3):519–530.
2.- Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in haemodialysis patients: the USRDS waves 1, 3, and 4 study. JASN. 2005;16(6):1788–1793.
3.- Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance haemodialysis. J Am Soc Nephrol. 2004;15(8):2208–2218.
4.-Kimata N, Albert JM, Akiba T, et al. Association of mineral metabolism factors with all-cause and cardiovascular mortality in haemodialysis patients: the Japan dialysis outcomes and practice patterns study. Hemodial Int. 2007;11(3):340–348.
5.- Ying L, Wen-Chin L, Ben-Chung C, et al. Association between the achievement of target range CKD-MBD markers and mortality in prevalent haemodialysis patients in Taiwan by using the kidney disease: improving global outcomes clinical guidelines. Biomed Res Int. 2016:1523124.
6.- KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)Kidney International Supplements. 2017; 7: 1–59.
7.- Pereira L, Magalhaes J, Mendonça L, et al. Evaluation of Renal Osteodystrophy and Serum Bone-Related Biomarkers in a Peritoneal Dialysis Population. J Bone Miner Res. 2022; 37(9):1689-1699.
8.- Cozzolino M, Gallieni M, Chiarelli G, et al. Calcium and phosphate handling in peritoneal dialysis. Contrib Nephrol. Basel, Karger. 2006;150:214– 225.
9.- Cozzolinoa M, Stucchia A, Rizzoa MA, et al. Phosphate Control in Peritoneal Dialysis. Contrib Nephrol. Basel, Karger. 2012;178:116–123.
10.- Pereira L, Mendonc L, Magalhães J, et al. Vascular calcification in peritoneal dialysis patients and its association with bone-derived molecules and bone Histomorphometry. Nefrologia. 2024;44(2):224–232.
11.- Barreto F, Costa C, Reis L et al. Bone biopsy in nephrology practice. J Bras Nefrol
. 2018;40(4):366-374.
12.-Fusaro M, Re Sartò GV, Gallieni M et al. Time for Revival of Bone Biopsy with Histomorphometric Analysis in Chronic Kidney Disease (CKD):Moving from Skepticism to Pragmatism. Nutrients. 2022;14:1742.
13.- Ronco C, Rosner MH, Crepaldi. Phosphate Control in Peritoneal Dialysis. Contrib Nephrol. Basel, Karger. 2012;178:116–123.
14.- Botelho C, Rodrigues A, Santos O. Phosphate removal in peritoneal dialysis regimens: an underestimated adequacy parameter. NDT Plus. 2010;33(suppl 3):477– 478.
15.- Schmitt CP, Schaefer F, Huber D, et al: 1,25(OH)2- vitamin D3 reduces spontaneous and hypocalcemia- stimulated pulsatile component of parathyroid hormone secretion. J Am Soc Nephrol. 1998;9:54–62.
16.-Nagy E, Sobh M, Abdalbary M et al. Is Adynamic Bone Always a Disease? Lessons from Patients with Chronic Kidney Disease. J. Clin. Med. 2022;11:7130.
17.- Sprague, S.M.; Bellorin-Font, E.; Jorgetti, V. et al. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am. J. Kidney Dis. 2016; 67:559–566.
18.-Wang AY. Calcium balance and negative impact of calcium load in peritoneal dialysis patients. Perit Dial Int. 2014;34(4):345-52.
19.- Gotch FA, Kotanko P, Thijssen S, et al. The KDIGO guideline for dialysate calcium will result in an increased incidence of calcium accumulation in hemodialysis patients. Kidney Int. 2010; 78:343–50.
20.- Hill KM, Martin BR, Wastney ME et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3–4 chronic kidney disease. Kidney Int. 2013; 83:959–66.
21.-Spasovski G, Gelev S, Masin-Spasovska J et al. Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium. Bone. 2007; 40:698–703.
22.-Sethi S, Dhooria HS, Goyal S. Study on the Effect of Low Calcium Dialysate on Biochemical Profile of Adynamic Bone Disease in Patients on Maintenance Hemodialysis. Saudi J Kidney Dis Transpl. 2023;34(3):224-234.
23.-Mathew S, Lund R, Strebeck F et al. Reversal of the Adynamic Bone Disorder and Decreased Vascular Calcification in Chronic Kidney Disease by Sevelamer Carbonate Therapy. Journal of the American Society of Nephrology. 2007;18(1):122-130.
24.- Ferreira A, Fraza˜o JM, Monier-Faugere MC et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 2008; 19: 405–412.
25.-Frazao J and Adragao T. Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival data. Kidney International.2008;74: S38–S43.
26.- Nigwekar SU, Brunelli SM, Meade D, et al: Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am Soc Nephrol.2013; 8: 1162–1170.
27.-O’Neill WC, Hardcastle KI. The chemistry of thiosulfate and vascular calcification. Nephrol Dial Transplant.2012;27:5216.
28.-Malbos S, Urena-Torres P, Cohen-Solal M et al. Sodium thiosulphate treatment of uraemic tumoral calcinosis. Rheumatology.2014;53:547-551.
29.- Yatzidis H, Agroyannis B. Sodium thiosulfate treatment of soft-tissue calcifications in patients with end-stage renal disease. Perit Dial Bull. 1987;7:2502.
30.- Kyriakopoulos G, Kontogianni K. Sodium thiosulfate treatment of tumoral calcinosis in patients with end-stage renal disease. Ren Fail.1990;12:2139.
31.- Papadakis JT, Patrikarea A, Digenis GE et al. Sodium thiosulfate in the treatment of tumoral calcifications in a hemodialysis patient without hyperparathyroidism. Nephron 1996;72:30812.